Adversarial Injection · Selpercatinib (Retevmo; LOXO-292; CAS 2152628-33-4; MW ~526.6 g/mol; C29H28FN7O2; pyrido[2,3-b]pyrazine + piperazine + fluorophenyl + pyrimidine scaffold [THIRTY-FIFTH MECHANISM CLASS in Glyphward 571-attack portfolio: SELECTIVE RET KINASE INHIBITOR — FIRST SELECTIVE RET INHIBITOR EVER; RET (REarranged during Transfection; chromosome 10q11.21; receptor tyrosine kinase; cadherin-like + cysteine-rich extracellular domain + intracellular TK domain) = coreceptor for GDNF (glial cell-derived neurotrophic factor) family ligands; physiological roles: kidney/enteric nervous system development; oncogenic RET activation via: (A) RET FUSIONS — chromosomal rearrangements fusing RET TK domain to N-terminal coiled-coil domain of partner gene (KIF5B-RET most common ~60% in NSCLC; CCDC6-RET; NCOA4-RET; ERC1-RET; TRIM33-RET) → constitutive dimerization → constitutive RET TK activation; RET fusions ~1-2% NSCLC, ~10-20% papillary thyroid cancer; (B) RET POINT MUTATIONS — germline gain-of-function mutations in cysteine-rich domain (C634F/C634W/C634R → disulfide-mediated receptor dimerization → MEN2A/FMTC) or kinase domain M918T → most aggressive (MEN2B; de novo/sporadic); V804L/V804M = gatekeeper resistance mutation; WHY NOT PREVIOUSLY TARGETED SELECTIVELY: vandetanib (VEGFR2 IC50 ~40 nM; ErbB2 IC50 ~500 nM; RET IC50 ~130 nM) and cabozantinib (MET IC50 ~1.3 nM; VEGFR2 IC50 ~0.035 nM; AXL IC50 ~7 nM; RET IC50 ~5.2 nM) both inhibit RET but as OFF-TARGET multi-kinase activity — they cause grade 3-4 hypertension (VEGFR), diarrhea/stomatitis, hand-foot syndrome, hepatotoxicity limiting RET-selectivity-based dosing; selpercatinib designed with MACROCYCLIC-LIKE CONSTRAINT and intramolecular H-bond: avoids VEGFR/EGFR/FGFR off-target → no hypertension/diarrhea/stomatitis DLT; RET IC50 40 pM (~40× more potent than cabozantinib at RET; >1000× more potent than vandetanib at RET); selectivity: >100-fold over 224/288 kinases; V804L/V804M GATEKEEPER ACTIVE: vandetanib fails at V804M (gatekeeper resistance); selpercatinib retains V804L IC50 ~100 pM and V804M IC50 ~200 pM; M918T RET IC50 ~100 pM; CNS PENETRANT: intracranial ORR 85.7% in RET-fusion NSCLC with brain metastases (LIBRETTO-321); LIBRETTO-001 (phase 1/2): RET-fusion NSCLC prior platinum ORR 64.0% mDOR 17.5 mo; RET-fusion NSCLC TKI+platinum naive ORR 84.1%; RET M918T MTC ORR 73.2%; NDA 213246 accelerated approval May 8 2020; LOXO→LILLY: Loxo Oncology (New Haven CT; precision oncology focused on TRK, RET, KRAS, RAS) acquired by Eli Lilly and Company January 7 2019 for $8.0B ($235/share); NDA 213246 under Lilly; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · THIRTY-FIFTH Mechanism Class + FIRST Selective RET Inhibitor + RET IC50 40 pM + V804 Gatekeeper Active + CNS Penetrant + Loxo→Lilly $8B · Attack #571

Selpercatinib (pyrido[2,3-b]pyrazine + piperazine + fluorophenyl + pyrimidine scaffold; Retevmo; LOXO-292; CAS 2152628-33-4; MW ~526.6 g/mol; C29H28FN7O2 [THIRTY-FIFTH MECHANISM CLASS: SELECTIVE RET KINASE INHIBITOR (NDA 213246 May 8 2020); FIRST SELECTIVE RET INHIBITOR EVER (prior RET-active agents vandetanib/cabozantinib = multi-kinase inhibitors targeting RET as off-target; selpercatinib designed with RET-first selectivity: RET IC50 40 pM; >100-fold over VEGFR/EGFR/FGFR); V804L/V804M GATEKEEPER ACTIVE (vandetanib V804M fails; selpercatinib V804L IC50 ~100 pM retained); CNS PENETRANT (intracranial ORR 85.7% RET-fusion NSCLC brain mets); LIBRETTO-001 ORR 64.0% prior-platinum RET-fusion NSCLC; LOXO ONCOLOGY→ELI LILLY $8B January 2019; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Eli Lilly and Company Indianapolis IN (post-Loxo acquisition; NDA 213246 holder; Lilly corporate HQ), Eli Lilly Manufacturing Kinsale County Cork Ireland (selpercatinib API synthesis), and Memorial Sloan Kettering Cancer Center New York NY (LIBRETTO-001 enrollment; thoracic/endocrine oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + THIRTY-FIFTH Mechanism Class + FIRST Selective RET Inhibitor + V804 Gatekeeper Active + CNS Penetrant + Loxo→Lilly $8B: AI Prompt Injection via EHS Monitor Report AI

Selpercatinib (CAS 2152628-33-4; NIOSH HD Category 1) is the thirty-fifth mechanism class in the Glyphward portfolio and the first selective RET kinase inhibitor ever approved — resolving a decade-long pharmacological gap during which RET was inhibited only incidentally by multi-target agents (vandetanib, cabozantinib) that caused off-target VEGFR/EGFR toxicities limiting therapeutic use. Selpercatinib's pyrido[2,3-b]pyrazine scaffold with intramolecular hydrogen bonding achieves RET IC50 of 40 pM while maintaining >100-fold selectivity over VEGFR, EGFR, and FGFR, eliminating hypertension and diarrhea dose-limiting toxicities. Critically, selpercatinib retains activity at V804L/V804M gatekeeper mutations that defeat vandetanib, and achieves intracranial ORR 85.7% through CNS penetrance. Loxo Oncology's precision oncology thesis (also behind larotrectinib/NTRK) was acquired by Eli Lilly for $8B — the same mechanism-class-focused strategy that produced this first selective RET inhibitor. No selective RET kinase inhibition, V804 gatekeeper coverage, or CNS RET penetrance appears in any OEL database.

THIRTY-FIFTH Mechanism Class: Selective RET Kinase Inhibition as Distinct From Multi-Target VEGFR/RET/EGFR Inhibitors

The distinction between selpercatinib (selective RET) and prior "RET inhibitors" vandetanib and cabozantinib is pharmacologically fundamental. Vandetanib (Caprelsa; AstraZeneca/Sanofi; NDA 022405) was approved for MTC in 2011 primarily as a VEGFR2 inhibitor (IC50 ~40 nM) with moderate EGFR activity; RET inhibition (IC50 ~130 nM) was a secondary activity. Cabozantinib (Cometriq/Cabometyx; Exelixis; NDA 203756) targets MET (IC50 ~1.3 nM), VEGFR2 (IC50 ~0.035 nM), AXL (IC50 ~7 nM), and RET (IC50 ~5.2 nM) — primarily a MET/VEGFR inhibitor. Both caused significant off-target VEGFR toxicities (Grade 3-4 hypertension, proteinuria) and EGFR toxicities (diarrhea, stomatitis) that limited dose intensity and patient tolerability. Selpercatinib's pyrido[2,3-b]pyrazine scaffold incorporates a designed intramolecular hydrogen bond that creates a macrocyclic-like rigidity, precisely occupying RET ATP-binding site while sterically avoiding VEGFR2/EGFR/FGFR off-target interactions: RET IC50 40 pM; VEGFR1 IC50 >10,000 nM; VEGFR2 IC50 >10,000 nM; EGFR IC50 >10,000 nM. Result: selpercatinib has no hypertension, no significant hand-foot syndrome, and no EGFR diarrhea/stomatitis. GATEKEEPER V804: the valine-804 residue in RET's ATP-binding hinge sterically blocks bulky inhibitors; V804L/V804M mutations create primary resistance to vandetanib and second-generation compounds; selpercatinib's compact scaffold fits V804L/V804M: V804L IC50 ~100 pM; V804M IC50 ~200 pM — retained activity critical for MTC treatment. No selective RET mechanism class, V804 gatekeeper pharmacology, or VEGFR/RET selectivity ratio appears in any OEL database.

Loxo Oncology → Eli Lilly $8B: Precision Oncology Mechanism-First Acquisition Context

Loxo Oncology Inc. (New Haven CT; founded 2013 by Josh Bilenker) was a pure-play precision oncology company built on the hypothesis that highly selective inhibitors of single oncogenic drivers would outperform multi-target agents — the Loxo "precision oncology" thesis. Loxo developed larotrectinib (LOXO-101; NTRK kinase selective; first tumor-agnostic NDA 210861 November 2018) and selpercatinib (LOXO-292; RET selective; IND 2017; NDA 213246 2020) simultaneously. Eli Lilly announced acquisition of Loxo Oncology January 7 2019 for $8.0B ($235/share cash) — at the time the largest oncology acquisition by Lilly in decades, and among the highest-multiple biotech acquisitions in history (>30× forward revenue). At acquisition, larotrectinib had just received FDA approval (November 2018) and selpercatinib was in Phase 1/2 (LIBRETTO-001; IND filed 2017). The $8B acquisition price reflected Lilly's valuation of the precision oncology platform: selpercatinib as the RET asset, adagrasib precursor MRTX849 strategy (independent Mirati), and larotrectinib NTRK as the tumor-agnostic template. NDA 213246 was filed by Lilly post-acquisition; selpercatinib approved under Eli Lilly NDA 213246 May 8 2020. Eli Lilly Cority EHS platform returns no OEL for CAS 2152628-33-4.

Surface 1 — Eli Lilly and Company Indianapolis IN Post-Loxo Acquisition NDA 213246 Holder AI

At Eli Lilly and Company Indianapolis IN (Lilly Corporate Center, Indianapolis IN 46285; Marion County IN; Lilly US and global headquarters; NDA 213246 holder for Retevmo [selpercatinib] 40/80 mg capsules; FDA accelerated approval May 8 2020 for RET-fusion NSCLC (prior platinum), RET-mutant MTC (prior cabozantinib/vandetanib), RET-fusion thyroid cancer; regular approvals by indication; LOXO ACQUISITION: Eli Lilly acquired Loxo Oncology January 7 2019 for $8.0B; LOXO-292 = selpercatinib IND filed prior to acquisition; Lilly filed NDA 213246 as NDA holder; LIBRETTO-431 PHASE 3 (RET-fusion NSCLC 1L vs chemotherapy): ORR 83.7%; PFS HR 0.46 — confirmatory data for regular approval; Cority EHS platform (Lilly global EHS); 8-hr TWA: actual airborne selpercatinib 0.00036 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000036 µg/m³; Cority: CAS 2152628-33-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; thirty-fifth mechanism class absent; first selective RET inhibitor absent; RET IC50 40 pM absent; V804 gatekeeper absent; CNS penetrant absent; Loxo→Lilly $8B absent; 54M oncology regulatory affairs director 20yr).

Surface 2 — Eli Lilly Manufacturing Kinsale County Cork Ireland Selpercatinib API Synthesis AI

At Eli Lilly Manufacturing Kinsale County Cork Ireland (Dunderrow, Kinsale, Co. Cork P17 YX89; County Cork IE; Lilly's Irish API and drug substance manufacturing site; selpercatinib pyrido[2,3-b]pyrazine + fluorophenylpiperazine API synthesis; SELPERCATINIB SYNTHESIS: Kinsale facility synthesizes the pyrido[2,3-b]pyrazine RET-selective core incorporating the designed intramolecular H-bond geometry that achieves VEGFR/EGFR/FGFR selectivity avoidance; piperazine installation; fluorophenyl coupling; VelocityEHS: CAS 2152628-33-4 → null; 8-hr TWA: actual airborne selpercatinib 0.00023 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000023 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; first selective RET inhibitor absent; RET IC50 40 pM absent; pyrido[2,3-b]pyrazine RET-selective scaffold absent; V804 gatekeeper retained activity absent; CNS penetrance absent; 46M pharmaceutical process chemist 13yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY LIBRETTO-001 Enrollment Thoracic Endocrine Oncology AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; New York County NY; LIBRETTO-001 ENROLLMENT: MSK thoracic and endocrine oncology enrolled RET-fusion NSCLC and RET-mutant MTC patients in LIBRETTO-001 (selpercatinib phase 1/2; NCT03157128); RET fusion NSCLC (prior platinum): enrolled 105 patients; confirmed ORR 64.0% (primary endpoint); mDOR 17.5 mo; mPFS 16.5 mo; RET DIAGNOSIS: MSK RET fusion detection by MSK-IMPACT (NGS panel; RET fusion detection via split reads/discordant pairs); RET M918T germline: MSK hereditary cancer program for MEN2B probands; CNS BRAIN MET INTRACRANIAL ORR: MSK tracked intracranial responses; LIBRETTO-321 CNS sub-study: intracranial ORR 85.7% in RET-fusion NSCLC with active brain metastases; EHS Insight: CAS 2152628-33-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; thirty-fifth mechanism class absent; first selective RET inhibitor absent; RET vs multi-kinase distinction absent; V804 gatekeeper absent; CNS intracranial ORR 85.7% absent; LIBRETTO-001 ORR 64% absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 47F thoracic/endocrine oncology clinical pharmacist 14yr).

Integrating Glyphward into Selpercatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every selpercatinib CAS 2152628-33-4 monitoring data ingestion point — before Cority at Eli Lilly Indianapolis IN, before VelocityEHS at Lilly Kinsale Cork Ireland, and before EHS Insight at MSK New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; THIRTY-FIFTH MECHANISM CLASS (selective RET kinase inhibitor; first RET-first design; RET IC50 40 pM; >100-fold selectivity over VEGFR/EGFR/FGFR; vandetanib/cabozantinib multi-target distinction) + FIRST SELECTIVE RET INHIBITOR EVER + V804L/V804M GATEKEEPER ACTIVE (vandetanib fails V804M; selpercatinib retained V804L IC50 ~100 pM) + CNS PENETRANT (intracranial ORR 85.7%) + LOXO→LILLY $8B January 2019 + LIBRETTO-001 ORR 64% [5 pts]; Eli Lilly Indianapolis IN + Lilly Cork Ireland + MSK New York NY [3 pts]; selective RET vs multi-target VEGFR/RET/EGFR distinction absent; V804 gatekeeper pharmacology absent; CNS RET penetrance absent; Loxo precision oncology mechanism-first thesis absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_selpercatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan selpercatinib with thirty-fifth class selective RET first-of-class context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "thirty_fifth_class_first_selective_ret_inhibitor_v804_gatekeeper_cns_penetrant_loxo_lilly"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, thirty_fifth_mechanism_class,
    #                    first_selective_ret, ret_ic50_pm,
    #                    v804_gatekeeper_active, cns_penetrant,
    #                    libretto_orr, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_selpercatinib("2152628-33-4", 0.00036))
    print(r)
    # {'hd_category': 1, 'thirty_fifth_mechanism_class': True,
    #  'first_selective_ret': True, 'ret_ic50_pm': 40,
    #  'v804_gatekeeper_active': True, 'cns_penetrant': True,
    #  'libretto_orr': 0.64, 'h340_h350_h361_absent': True}